Jubilant Pharmova Ltd
Jubilant Pharmova Ltd (JUBLPHARMA) last reported results for the quarter ended Jun 2026, with sales of ₹2,229 crore and net profit of ₹56 crore. The next scheduled event is a fundraising on 12 Oct 2026. The stock last traded at ₹976, a market capitalisation of ₹15,540 crore, on a P/E of 40.0. Over the past 52 weeks the stock has ranged between ₹784 and ₹1,185. Figures are as of 6 Oct 2026 and are not real time.
Jubilant Pharmova Ltd share price and key metrics
- Current price
- ₹976
- Market cap
- ₹15,540 cr
- Stock P/E
- 40.0
- Book value
- ₹445
- ROE
- 6.53%
- ROCE
- 8.99%
- Dividend yield
- 0.51%
- 52w high / low
- 1185/784
Metrics as of 6 Oct 2026. Not real time.
Track Jubilant Pharmova Ltd
Cruxal reads every Jubilant Pharmova Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Jubilant Pharmova Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 6%
- 3 Years
- 10%
- TTM
- 16%
- 10 Years
- 1%
- 5 Years
- -13%
- 3 Years
- 47%
- TTM
- -20%
- 10 Years
- 6%
- 5 Years
- 9%
- 3 Years
- 32%
- 1 Year
- -11%
- 10 Years
- 9%
- 5 Years
- 3%
- 3 Years
- 5%
- Last Year
- 7%
Jubilant Pharmova Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,229 cr, up 17.3% from ₹1,901 cr a year earlier. Net profit was ₹56 cr, down 45.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,122 | 2,290 | 2,229 |
| Expenses | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 | 1,833 | 1,951 | 1,981 |
| Operating profit | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 |
| OPM % | 17% | 16% | 18% | 15% | 17% | 14% | 15% | 11% |
| Other income | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 |
| Interest | 61 | 56 | 53 | 49 | 50 | 56 | 56 | 54 |
| Depreciation | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 |
| Profit before tax | 144 | 130 | 206 | 154 | 190 | 93 | 176 | 86 |
| Tax % | 29% | 23% | 27% | 34% | 37% | 40% | 32% | 35% |
| Net profit | 102 | 101 | 151 | 102 | 120 | 56 | 119 | 56 |
| EPS (₹) | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 | 3.51 | 7.50 | 3.55 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Jubilant Pharmova Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,703 | 7,234 | 8,280 | 8,608 |
| Operating profit | 1,352 | 1,522 | 1,744 | 1,548 | 1,403 | 1,150 | 779 | 901 | 1,173 | 1,260 | 1,218 |
| OPM % | 23% | 20% | 19% | 26% | 23% | 19% | 12% | 13% | 16% | 15% | 14% |
| Net profit | 575 | 634 | 577 | 898 | 836 | 413 | -65 | 73 | 836 | 398 | 351 |
| EPS (₹) | 36.14 | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 25.02 | 22.11 |
TTM is the trailing twelve months to the most recent quarter.
Jubilant Pharmova Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 3,420 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,418 | 6,239 | 7,077 |
| Borrowings | 4,045 | 3,469 | 4,840 | 4,808 | 2,830 | 3,192 | 3,677 | 3,664 | 2,731 | 3,615 |
| Other liabilities | 1,417 | 1,902 | 1,670 | 1,898 | 1,192 | 1,319 | 1,853 | 2,240 | 3,598 | 4,564 |
| Total liabilities | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 15,272 |
| Fixed assets | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,091 | 5,176 | 6,966 |
| CWIP | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,562 | 2,103 | 3,630 | 4,040 |
| Investments | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 | 44 | 61 |
| Other assets | 3,006 | 3,262 | 4,654 | 5,133 | 3,017 | 3,631 | 3,928 | 4,101 | 3,735 | 4,205 |
| Total assets | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 15,272 |
As reported by the company. Total assets equal total liabilities by construction.
Jubilant Pharmova Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,268 | 1,303 | 1,122 | 1,543 | 1,784 | 838 | 661 | 971 | 1,072 | 1,227 |
| Cash from investing | -465 | -614 | -1,018 | -267 | -727 | -323 | -474 | -596 | 512 | -1,143 |
| Cash from financing | -686 | -901 | 657 | -1,050 | -1,709 | -33 | -157 | -432 | -1,453 | 95 |
| Net cash flow | 117 | -212 | 761 | 225 | -652 | 482 | 30 | -58 | 132 | 179 |
| Free cash flow | 806 | 819 | 473 | 975 | 1,270 | 241 | -135 | 83 | -38 | -120 |
| CFO / operating profit | 104% | 103% | 84% | 116% | 155% | 90% | 111% | 131% | 112% | 114% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Jubilant Pharmova Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 15% | 15% | 16% | 15% | 12% | 10% | 3% | 7% | 10% | 9% |
| Debtor days | 63 | 55 | 51 | 79 | 49 | 55 | 56 | 50 | 45 | 47 |
| Inventory days | 223 | 177 | 147 | 463 | 268 | 308 | 268 | 220 | 178 | 170 |
| Days payable | 137 | 145 | 106 | 273 | 124 | 139 | 160 | 146 | 158 | 170 |
| Cash conversion cycle | 149 | 87 | 92 | 268 | 194 | 224 | 165 | 124 | 65 | 47 |
| Working capital days | 50 | 45 | 45 | 62 | 74 | 56 | 57 | 56 | 16 | 13 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Jubilant Pharmova Ltd shareholding pattern
Promoters held 47.67% at Jun 2026, broadly unchanged since Jun 2025. FIIs 15.87% and DIIs 12.40%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.67% | 50.67% | 50.67% | 47.67% | 47.67% | 47.67% | 47.67% | 47.67% |
| FIIs | 17.94% | 16.96% | 17.23% | 17.40% | 16.56% | 15.96% | 15.90% | 15.87% |
| DIIs | 5.66% | 6.99% | 7.05% | 9.52% | 10.53% | 11.23% | 11.63% | 12.40% |
| Public | 25.17% | 24.82% | 24.48% | 24.83% | 24.60% | 24.57% | 24.25% | 23.50% |
| No. of shareholders | 89,456 | 1,02,442 | 96,526 | 99,673 | 93,336 | 90,133 | 86,347 | 82,703 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Jubilant Pharmova Ltd events
The next scheduled event is a fundraising on 12 Oct 2026.
- FundraisingRaising funds through issuance of Non-Convertible Debentures (NCDs) and/or other securities
See the full results calendar for every Indian company reporting in the next 30 days.
Jubilant Pharmova Ltd corporate filings
- Jubilant Pharmova files regulatory disclosure under Regulation 30 on October 8, 2026Company Updatelow impact
Cruxal's analysis: The company, a small-cap with a market cap of approximately 15,740 crore, has submitted a…
Read the full analysis - Jubilant Pharmova schedules Board Meeting to consider raising funds via NCD issuanceBoard Meetingmedium impact
Cruxal's analysis: Jubilant Pharmova Limited has announced a Board meeting scheduled for October 12, 2026…
Read the full analysis - Compliance Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the Quarter ended September 30, 2026Company Updatelow impact
- Intimation regarding Closure of Trading Window for the Quarter ended September 30, 2026Insider Trading / SASTlow impact
- Jubilant Pharmova Limited issues regulatory notice regarding withholding of final dividend for FY 2025-26 due to incomplete KYCCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova Limited has issued a formal intimation to shareholders holding…
Read the full analysis - Jubilant Pharmova provides update on USFDA inspection status for Spokane facilityCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova has issued a regulatory update regarding its Spokane facility following…
Read the full analysis - Jubilant Pharmova Limited receives GST Show Cause NoticeCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova Limited has received a Show Cause Notice (SCN) regarding Goods and…
Read the full analysis - Jubilant Pharmova Ltd announces newspaper publication regarding relodgement and KYC updationCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova Ltd has issued a mandatory newspaper publication notice concerning the…
Read the full analysis - Jubilant Pharmova subsidiary Jubilant Generics receives Show Cause NoticeCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova Ltd has disclosed that its subsidiary, Jubilant Generics Limited, has…
Read the full analysis - Jubilant Pharmova Limited concludes 48th AGM; reports FY26 revenue of 8,300 crore and declares dividend of 5 INR per shareAGM/EGMlow impact
Cruxal's analysis: Jubilant Pharmova Limited successfully concluded its 48th Annual General Meeting, where…
Read the full analysis - Jubilant Pharmova Receives USFDA Approval for New Isolator-Based Fill and Finish Line at Spokane FacilityCompany Updatehigh impact
Cruxal's analysis: Jubilant Pharmova Limited has secured USFDA approval for commercial batch manufacturing…
Read the full analysis - Jubilant Pharmova Limited announces successful re-appointment of Managing Director and Joint Managing Director via postal ballotAGM/EGMlow impact
Cruxal's analysis: Jubilant Pharmova Limited has confirmed the re-appointment of Mr. Priyavrat Bhartia as…
Read the full analysis - Jubilant Pharmova Ltd publishes mandatory newspaper advertisements regarding regulatory complianceCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova Ltd has released the mandatory newspaper publications as per Regulation…
Read the full analysis - Jubilant Pharmova releases investor presentation following recent quarterly resultsCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova has filed an investor presentation dated August 10, 2026, providing…
Read the full analysis - Jubilant Pharmova Q1 FY27 Consolidated Profit Declines to 564 crore Amid Margin PressureBoard Meetinghigh impact
Cruxal's analysis: Jubilant Pharmova Limited reported consolidated revenue from operations of 2,229 crore…
Read the full analysis - Jubilant Pharmova schedules analyst/investor meeting for August 5, 2026Company Updatelow impact
Cruxal's analysis: Jubilant Pharmova has issued an intimation regarding an analyst/investor meeting…
Read the full analysis - Jubilant Pharmova Limited Reschedules Board Meeting for Q1 FY27 Financial Results to August 10, 2026Company Updatelow impact
Cruxal's analysis: Jubilant Pharmova Limited has announced the postponement of its Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.